Sequent Scientific receives WHO prequalification approval for Albendazole API
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The robotic surgery program has continually pushed the boundaries of medical technology
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Becomes the first rehab & recovery center in east India to earn NABH accreditation
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The partnership marks a significant milestone in integrating digital health education into medical curricula
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
This project is supported by the Irish Government through IDA Ireland
Morepen Labs successfully raised Rs. 200 Crore through QIP
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Subscribe To Our Newsletter & Stay Updated